Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Machida, Kazuya ^b   Eschrich, Steven ^a   Li, Jiannong ^a   Bai, Yun ^a   Koomen, John ^a   Mayer, Bruce J ^b   Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; K RAS PROTEIN; PHOSPHOTYROSINE; PROTEIN SH2; SCATTER FACTOR RECEPTOR; TYROSINE;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; ONCOGENE RAS; PATHOLOGY; PHOSPHORYLATION; SRC HOMOLOGY DOMAIN; TUMOR CELL LINE;

CELL LINE, TUMOR; GENES, RAS; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TYROSINE;

EID: 78149463029     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013470     Document Type: Article

References (52)

1. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355-365.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
4. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
5. Davies H, Hunter C, Smith R, Stephens P, Greenman C, et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595.
6. Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932.
7. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, et al. (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 3: 2795-2803.
8. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, et al. (2007) A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 67: 3529-3534.
9. Song L, Morris M, Bagui T, Lee FY, Jove R, et al. (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66: 5542-5548.
10. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
11. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, et al. (2009) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 5: 4423-4430.
12. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, et al. (2008) Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 7: 3408-3419.
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
14. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
15. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
16. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, et al. (2008) Firstline gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442-2449.
17. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655.
18. Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, et al. (2006) Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 7: 289.
19. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, et al. (2008) Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 14: 6963-6973.
20. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937.
21. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
22. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
23. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290.
24. Kikuchi T, Carbone DP (2007) Proteomics analysis in lung cancer: challenges and opportunities. Respirology 12: 22-28.
25. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, et al. (2008) Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancerspecific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 105: 14112-14117.
26. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105: 692-697.
27. Dierck K, Machida K, AV, Thimm J, Horstmann M, et al. (2006) Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosinespecific DNA-tagged SH2 domains. Nat Meth 3: 737-744.
28. Machida K, Thompson CM, Dierck K, Jablonowski K, Kärkkäinen S, et al. (2007) High-throughput phosphotyrosine profiling using SH2 domains. Mol Cell 26: 899-915.
29. Pawson T (2004) Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116: 191-203.
30. Machida K, Mayer BJ (2005) The SH2 domain: versatile signaling module and pharmaceutical target. Biochim Biophys Acta Proteins and Proteomics 1747: 1-25.
31. Liu BA, Jablonowski K, Raina M, Arce M, Pawson T, et al. (2006) The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol Cell 22: 851-868.
32. Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D (1993) Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 363: 88-92.
33. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, et al. (1992) Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360: 689-692.
34. Chong YP, Mulhern TD, Cheng HC (2005) C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)-endogenous negative regulators of Src-family protein kinases. Growth Factors 23: 233-244.
35. Nakamura Y, Matsubara D, Goto A, Ota S, Sachiko O, et al. (2008) Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci 99: 14-22.
36. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, et al. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63: 7345-7355.
37. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
38. Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, et al. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 104: 13283-13288.
39. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063.
40. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
41. Antoku S, Mayer BJ (2009) Distinct roles for Crk adaptor isoforms in actin reorganization induced by extracellular signals. J Cell Sci 122: 4228-4238.
42. Rivera GM, Antoku S, Gelkop S, Shin SY, Hanks SK, et al. (2006) Requirement of Nck adaptors for actin dynamics and cell migration stimulated by PDGF-B. Proc Natl Acad Sci USA 103: 9536-9541.
43. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, et al. (2009) A gene expression signature associated with K-Ras addiction reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500.
44. Thomson S, Buck E, Petti F, Griffin G, Brown E, et al. (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.\. Cancer Res 65: 9455-9462.
45. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698.
46. Ptacek J, Snyder M (2006) Charging it up: global analysis of protein phosphorylation. Trends Genet 22: 545-554.
47. Schmelzle K, White FM (2006) Phosphoproteomic approaches to elucidate cellular signaling networks. Curr Opin Biotech 17: 406-414.
48. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
49. Dierck K, Machida K, Mayer BJ, Nollau P (2009) Profiling the tyrosine phosphorylation state using SH2 domains. Meth Mol Biol 527: 131-155.
50. Machida K, Mayer BJ (2009) Detection of protein-protein interactions by far-Western blotting. Meth Mol Biol 536: 318-329.
51. Nollau P, Mayer BJ (2001) Profiling the global tyrosine phosphorylation state by Src Homology 2 domain binding. Proc Natl Acad Sci USA 98: 13531-13536.
52. Storey JD, Tibshirani R (2003) Statistical significance for genome-wide studies. Proc Natl Acad Sci USA 100: 9440-9445.